Sanofi may win U.S. approval of $3 billion eczema drug by March

(Reuters) - French drugmaker Sanofi  and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, by next March.

Source: Reuters: Health - September 26, 2016 Category: Consumer Health News Tags: healthNews Source Type: news